Table 1. Characteristics of studies that met our inclusion criteria.

	Author	Year	Country	Sample size	Study type	Follow-up in weeks	Intervention	Undetectable HBV DNA level	Study quality
TDF vs. ENT	Batirel et al.28	2014	Turkey	195	Retrospective study	48	Received TDF (245 mg/day) or ETV (0.5 mg/day)	20 IU/mL	Good
	Cai et al.19	2019	China	315	RCT	144	All the drugs, either TDF capsule or ETV capsule, were provided by Cosunter Pharmaceutical (Ningde, Fujian, China)	20 IU/mL	NA
	Centeno et al.34	2016	Spain	64	Retrospective study	48	Initiated treatment with TDF or ETV between January 1998 and 2013	20 IU/mL	Good
	Ceylan et al.29	2013	Turkey	117	Retrospective study	96	Treatment with TDF or ETV	20 IU/mL	Good
	Ha et al.30	2016	USA	556	Retrospective study	96	Either ETV 0.5 mg daily or TDF 300 mg daily	40 IU/mL	Good
	Jayakumar et al.31	2012	India	39	Prospective study	24	Treated with lamivudine (100 mg/day) plus adefovir (10 mg/day) combination ETV monotherapy (0.5 mg/day) and tenofovir monotherapy (300 mg/day)	400 copies/mL	Good
	Kayaaslan et al.32	2017	Turkey	252	Retrospective study	96	Therapy with ETV 0.5–1 mg/day or TDF 245 mg/day	20 IU/mL	Good
	Koike et al.22	2017	Japan	166	RCT	24	TDF 300 mg QD and ETV 0.5 mg QD	NA	NA
	Kwon et al.33	2015	Korea	79	Retrospective study	48	Treatment with TDF or ETV	20 IU/mL	Good
	Ozaras et al.36	2014	Turkey	251	Cohort study	72	Treatment with TDF or ETV	2*106 IU/mL	Good
	Park et al.37	2017	Korea	210	Cohort study	48	Treatment with TDF or ETV	20 IU/mL	Good
	Riveiro-Barciela et al.38	2017	Spain	611	Cohort study	60	ETV at dose of 0.5 or 1 mg per day, and TDF at dose of 245 mg per day	69 IU/mL	Good
	Pereira et al.42	2016	Brazil	294	Cross-sectional study	48	Treatment with TDF or ETV	NA	NA
	Shi et al.39	2016	China	96	Retrospective study	96	Treated orally with ETV at 0.5 mg/day (ETV group) and tenofovir at 300 mg/day (TDF group)	100 IU/mL	Good
	Sriprayoon et al.26	2016	Thailand	400	RCT	144	Receive either ETV 0.5 mg or TDF 300 mg daily	20 IU/mL	NA
	Yim et al.27	2018	Korea	40	RCT	48	One group received 300 mg of TDF once daily and the other received 0.5 mg of ETV once daily	120 copies/mL	NA
	Yu et al.41	2014	Korea	107	Retrospective study	48	Treated with TDF 300 mg daily, and the ETV group treated with ETV 0.5 mg daily	50 IU/mL	Good
TAF vs. TDF	Agarwal et al.15	2018	United Kingdom	1,298	RCT	48	Receive 25 mg TAF or 300 mg TDF	29 IU/mL	NA
	Buti et al.16	2016	Spain	425	RCT	96	Receive once-daily oral doses of TAF 25 mg or TDF 300 mg, each with matching placebo	29 IU/mL	NA
	Buti et al.17	2017	Spain	1,298	RCT	48	Receive oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg TAF (elvitegravir/cobicistat/emtricitabine/TAF) or 300 mg TDF (elvitegravir/cobicistat/emtricitabine /TDF)	29 IU/mL	NA
	Byrne et al.18	2018	Spain	1,298	RCT	96	Different doses of TAF (8, 25, 40 or 120 mg) or to TDF 300 mg	29 IU/mL	NA
	Chan et al.20	2016	China	873	RCT	96	Received TAF 25 mg orally once daily or TDF 300 mg orally once daily.	29 IU/mL	NA
TDF+ETV vs. TDF	Jeon et al.21	2017	Korea	54	RCT	96	Related with TDF monotherapy (n=12), TDF+LAM (n=19), or TDF+ETV (n=42)	12 IU/mL	NA
	Lim et al.23	2015	Korea	90	RCT	48	Receive TDF (300 mg/day) monotherapy or TDF and ETV (1 mg/day) combination therapy	15 IU/mL and 60 IU/mL	NA
	Lim et al.24	2017	Korea	192	RCT	144	After completing 48 weeks of randomized, parallel comparisons of TDF monotherapy (300 mg once daily) vs. TDF/ETV combination therapy, patients were eligible to continue TDF monotherapy (TDF-TDF group) or switch to TDF monotherapy (TDF/ETV-TDF group)	15 IU/mL and 60 IU/mL	NA
	Lok et al.25	2012	Turkey	379	RCT	96	Receive ETV 0.5 mg plus TDF 300mg once daily or ETV 0.5 mg once daily for 100 weeks	50 IU/mL	NA
	Lu et al.35	2014	USA	68	Retrospective cohort study	68	At least 12 months of ETV, and were switched to TDF monotherapy (n=25) or ETV+TDF (n=43)	60 IU/mL	Good
	Wang et al.40	2019	China	143	Retrospective study	143	CHB patients with PVR to ETV were switched to TDF monotherapy or TDF+ETV combination therapy	100IU/mL	Good